Monosomy of chromosome 10 associated with dysregulation of epidermal growth factor signaling in glioblastomas.

CONTEXT Glioblastomas--uniformly fatal brain tumors--often have both monosomy of chromosome 10 and gains of the epidermal growth factor receptor (EGFR) gene locus on chromosome 7, an association for which the mechanism is poorly understood. OBJECTIVES To assess whether coselection of EGFR gains on 7p12 and monosomy 10 in glioblastomas promotes tumorigenic epidermal growth factor (EGF) signaling through loss of the annexin A7 (ANXA7) gene on 10q21.1-q21.2 and whether ANXA7 acts as a tumor suppressor gene by regulating EGFR in glioblastomas. DESIGN, SETTING, AND PATIENTS Multidimensional analysis of gene, coding sequence, promoter methylation, messenger RNA (mRNA) transcript, protein data for ANXA7 (and EGFR), and clinical patient data profiles of 543 high-grade gliomas from US medical centers and The Cancer Genome Atlas pilot project (made public 2006-2008; and unpublished, tumors collected 2001-2008). Functional analyses using LN229 and U87 glioblastoma cells. MAIN OUTCOME MEASURES Associations among ANXA7 gene dosage, coding sequence, promoter methylation, mRNA transcript, and protein expression. Effect of ANXA7 haploinsufficiency on EGFR signaling and patient survival. Joint effects of loss of ANXA7 and gain of EGFR expression on tumorigenesis. RESULTS Heterozygous ANXA7 gene deletion is associated with significant loss of ANXA7 mRNA transcript expression (P = 1 x 10(-15); linear regression) and a reduction (mean [SEM]) of 91.5% (2.3%) of ANXA7 protein expression compared with ANXA7 wild-type glioblastomas (P = .004; unpaired t test). ANXA7 loss of function stabilizes the EGFR protein (72%-744% increase in EGFR protein abundance) and augments EGFR transforming signaling in glioblastoma cells. ANXA7 haploinsufficiency doubles tumorigenic potential of glioblastoma cells, and combined ANXA7 knockdown and EGFR overexpression promotes tumorigenicity synergistically. The heterozygous loss of ANXA7 in approximately 75% of glioblastomas in the The Cancer Genome Atlas plus infrequency of ANXA7 mutation (approximately 6% of tumors) indicates its role as a haploinsufficiency gene. ANXA7 mRNA transcript expression, dichotomized at the median, associates with patient survival in 191 glioblastomas (log-rank P = .008; hazard ratio [HR], 0.667; 95% confidence interval [CI], 0.493-0.902; 46.9 vs 74.8 deaths/100 person-years for high vs low ANXA7 mRNA expression) and with a separate group of 180 high-grade gliomas (log-rank P = .00003; HR, 0.476; 95% CI, 0.333-0.680; 21.8 vs 50.0 deaths/100 person-years for high vs low ANXA7 mRNA expression). Deletion of the ANXA7 gene associates with poor patient survival in 189 glioblastomas (log-rank P = .042; HR, 0.686; 95% CI, 0.476-0.989; 54.0 vs 80.1 deaths/100 person-years for wild-type ANXA7 vs ANXA7 deletion). CONCLUSION Haploinsufficiency of the tumor suppressor ANXA7 due to monosomy of chromosome 10 provides a clinically relevant mechanism to augment EGFR signaling in glioblastomas beyond that resulting from amplification of the EGFR gene.

[1]  D. Louis.  WHO classification of tumours of the central nervous system , 2007 .

[2]  K. Nelson,et al.  Epidermal growth factor (EGF) stimulates EGF receptor synthesis. , 1986, The Journal of biological chemistry.

[3]  Ronald W. Davis,et al.  Mechanisms of Haploinsufficiency Revealed by Genome-Wide Profiling in Yeast , 2005, Genetics.

[4]  O. Kallioniemi,et al.  Prognostic Impact of ANX7-GTPase in Metastatic and HER2-Negative Breast Cancer Patients , 2004, Clinical Cancer Research.

[5]  G. Nolan,et al.  Production of high-titer helper-free retroviruses by transient transfection. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[6]  I. Pastan,et al.  A novel effect of EGF on mRNA stability. , 1988, Nucleic acids research.

[7]  P. Duesberg,et al.  Multistep Carcinogenesis: A Chain Reaction of Aneuploidizations , 2003, Cell cycle.

[8]  Thomas D. Wu,et al.  Molecular subclasses of high-grade glioma predict prognosis, delineate a pattern of disease progression, and resemble stages in neurogenesis. , 2006, Cancer cell.

[9]  A. Verma.  MGMT Gene Silencing and Benefit From Temozolomide in Glioblastoma , 2006 .

[10]  R. O. Morgan,et al.  Deciphering function and mechanism of calcium-binding proteins from their evolutionary imprints. , 2006, Biochimica et biophysica acta.

[11]  J. Uhm.  Comprehensive genomic characterization defines human glioblastoma genes and core pathways , 2009 .

[12]  K. Chen,et al.  Annexin VII and Annexin XI Are Tyrosine Phosphorylated in Peroxovanadate-treated Dogs and in Platelet-derived Growth Factor-treated Rat Vascular Smooth Muscle Cells* , 1999, The Journal of Biological Chemistry.

[13]  M. Wigler,et al.  PTEN, a Putative Protein Tyrosine Phosphatase Gene Mutated in Human Brain, Breast, and Prostate Cancer , 1997, Science.

[14]  O. Mcbride,et al.  Divergent structure of the human synexin (annexin VII) gene and assignment to chromosome 10. , 1994, Biochemistry.

[15]  L. Mazzucchelli,et al.  An overview of the epidermal growth factor receptor fluorescence in situ hybridisation challenge in tumour pathology , 2008, Journal of Clinical Pathology.

[16]  S. Coons,et al.  Diagnostic and prognostic significance of genetic regional heterogeneity in meningiomas. , 2004, Neuro-oncology.

[17]  L. Smilenov,et al.  Tumor development: haploinsufficiency and local network assembly. , 2006, Cancer letters.

[18]  Sebastian Kadener,et al.  Mathematical model of the Drosophila circadian clock: loop regulation and transcriptional integration. , 2009, Biophysical journal.

[19]  M. Raffeld,et al.  ANXA7 expression represents hormone‐relevant tumor suppression in different cancers , 2007, International journal of cancer.

[20]  O. Kallioniemi,et al.  ANX7, a candidate tumor suppressor gene for prostate cancer , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[21]  T. Speed,et al.  Summaries of Affymetrix GeneChip probe level data. , 2003, Nucleic acids research.

[22]  T. Ried,et al.  Haploinsufficiency of Anx7 tumor suppressor gene and consequent genomic instability promotes tumorigenesis in the Anx7(+/-) mouse , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[23]  I. Pastan,et al.  Epidermal growth factor regulates the expression of its own receptor. , 1985, Proceedings of the National Academy of Sciences of the United States of America.

[24]  C. Futter,et al.  EGF stimulates annexin 1‐dependent inward vesiculation in a multivesicular endosome subpopulation , 2006, The EMBO journal.

[25]  J. Uhm.  An Integrated Genomic Analysis of Human Glioblastoma Multiforme , 2009 .

[26]  H. Pollard,et al.  Distinct effects of annexin A7 and p53 on arachidonate lipoxygenation in prostate cancer cells involve 5-lipoxygenase transcription. , 2006, Cancer research.

[27]  Joshua M. Korn,et al.  Comprehensive genomic characterization defines human glioblastoma genes and core pathways , 2008, Nature.

[28]  C. Svendsen,et al.  Human progenitor cells isolated from the developing cortex undergo decreased neurogenesis and eventual senescence following expansion in vitro. , 2006, Experimental cell research.

[29]  J. Issa,et al.  A simple method for estimating global DNA methylation using bisulfite PCR of repetitive DNA elements. , 2004, Nucleic acids research.

[30]  S. Moss,et al.  Annexins: linking Ca2+ signalling to membrane dynamics , 2005, Nature Reviews Molecular Cell Biology.

[31]  W. K. Alfred Yung,et al.  Identification of a candidate tumour suppressor gene, MMAC1, at chromosome 10q23.3 that is mutated in multiple advanced cancers , 1997, Nature Genetics.

[32]  Goberdhan P Dimri,et al.  Regulation of a Senescence Checkpoint Response by the E2F1 Transcription Factor and p14ARF Tumor Suppressor , 2000, Molecular and Cellular Biology.

[33]  Koji Yoshimoto,et al.  Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors. , 2005, The New England journal of medicine.

[34]  M. Ronaghi,et al.  A Sequencing Method Based on Real-Time Pyrophosphate , 1998, Science.

[35]  Carolina Wählby,et al.  In Situ Detection of Phosphorylated Platelet-derived Growth Factor Receptor β Using a Generalized Proximity Ligation Method* , 2007, Molecular & Cellular Proteomics.

[36]  Robert Tibshirani,et al.  A network model of a cooperative genetic landscape in brain tumors. , 2009, JAMA.

[37]  Joe W. Gray,et al.  Translating insights from the cancer genome into clinical practice , 2008, Nature.

[38]  B. Scheithauer,et al.  The 2007 WHO classification of tumours of the central nervous system , 2007, Acta Neuropathologica.

[39]  S. Horvath,et al.  Gene Expression Profiling of Gliomas Strongly Predicts Survival , 2004, Cancer Research.

[40]  S. Horvath,et al.  Gene expression analysis of glioblastomas identifies the major molecular basis for the prognostic benefit of younger age , 2008, BMC Medical Genomics.

[41]  U. Landegren,et al.  Direct observation of individual endogenous protein complexes in situ by proximity ligation , 2006, Nature Methods.

[42]  S. Sukumar,et al.  Significant allelic loss of ANX7region (10q21) in hormone receptor negative breast carcinomas. , 2004, Cancer letters.

[43]  O. Eidelman,et al.  Anx7 Is Required for Nutritional Control of Gene Expression in Mouse Pancreatic Islets of Langerhans , 2002, Molecular medicine.